Dr. Agarwal’s Health Care Share Price Drops; Sees 28% Revenue Jump in FY25 Results

Dr. Agarwal’s Health Care Limited announced its audited consolidated financial results for the quarter and twelve months ended March 31, 2025.

Q4 FY2025 Performance

The company achieved revenue from operations of ₹460 crore, marking a 31.9% year-on-year (YoY) growth. Revenue from Indian operations contributed ₹413 crore, growing 34.2% YoY, while mature facilities accounted for ₹332 crore, up 28.9% YoY.

The EBITDA stood at ₹146 crore, rising 15.1% YoY, with an EBITDA margin of 30.8%. Profit After Tax (PAT) for the quarter came in at ₹43 crore, reflecting a 3.0% YoY growth and a PAT margin of 8.9%. During this quarter, the company added 17 new facilities, bringing the total facility count to 236 as of March 31, 2025.

FY2025 Annual Performance

For the full financial year ended March 31, 2025 (12M FY2025), Dr. Agarwal’s Health Care posted revenue from operations of ₹1,711 crore, registering a 28.4% YoY growth. Indian operations contributed ₹1,538 crore, growing 32.4%, while revenue from mature facilities reached ₹1,206 crore, up 18.5%.

Service revenue made up 79% of the total operational revenue, while product sales accounted for 21%. The company posted an EBITDA of ₹502 crore, an increase of 23.6% YoY, with EBITDA margins at 28.6%. Net profit for the year stood at ₹110 crore, showing a 16.1% YoY rise with a PAT margin of 6.3%.

Over the year, 59 new facilities were added, of which 52 were new setups and 7 were acquisitions. Additionally, the company performed 2,82,326 surgeries in FY2025, marking a 28% YoY increase.

Management Commentary

Commenting on the results, Dr. Adil Agarwal, CEO, Dr. Agarwal’s Health Care Limited, said, “We are pleased to announce our first annual results post-listing, recording a strong 31.9% revenue growth that reflects the sustained momentum in our operations. In India, we expanded our network from 165 to 218 centres, reinforcing our commitment to accessible, high-quality eye care.”

He further stated, “We remain committed to growth and see significant untapped potential in the Indian eye care market. Organized eye care chains like ours currently serve just 13-15% of the market, while the remaining 85-87% is fragmented across standalone hospitals, clinics, community- and trustrun institutions, and government facilities. This fragmentation presents a compelling opportunity for us to consolidate and scale.”

“We aim to capitalize on this potential by increasing patient volumes per center, strengthening referral networks, executing targeted marketing initiatives, and maintaining an unwavering focus on patient satisfaction. With these growth drivers in place, we are committed to accelerating our financial performance in the years ahead and doing so by scaling smartly, growing responsibly, and leading purposefully,” stated the CEO.

Dr. Agarwal’s Health Care Share Price Performance

On May 29, 2025, Dr. Agarwal’s Health Care share price (NSE: AGARWALEYE) opened at ₹360.00, up from its previous close of ₹352.85. At 10:48 AM, the share price of Dr. Agarwal’s Health Care was trading at ₹348.90, down by 1.12% on the NSE.

Also Read: Glenmark FY25 Results: PAT Jumps 16.4% YoY & Revenue Up 12.8%!

Conclusion

Dr. Agarwal’s Health Care has delivered a financial and operational performance in FY2025, driven by expansion in India, consistent revenue growth, and an increase in surgical volumes.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.